Status:
WITHDRAWN
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
Lead Sponsor:
Imperial College London
Conditions:
Antiphospholipid Syndrome
Eligibility:
FEMALE
Phase:
PHASE1
PHASE2
Brief Summary
Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimeste...
Detailed Description
Over the last decade, the APS has emerged as most important treatable cause of recurrent miscarriages. The pathogenesis of fetal loss in this condition is still remains obscure. Despite the success of...
Eligibility Criteria
Inclusion
- History of 3 or more consecutive miscarriages and positive antiphospholipid antibodies on at least two occasions more than 6 weeks apart before becoming pregnant and an unsuccessful pregnancy with aspirin + heparin with a karyotype of miscarriage either unavailable or normal (46XX/ 46XY).
Exclusion
- Abnormal karyotype of women or partner, previous thromboembolism, SLE, diabetes mellitus, hypertension, sensitivity to aspirin, heparin and prednisolone, multiple pregnancy.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00180778
Start Date
October 1 2005
End Date
October 1 2005
Last Update
February 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Mary's Hospital
London, United Kingdom, W2 1NY